GlassScriptPhysician profile
John D Adams
NPI 1528263936
$8,225.65
in general payments reported to CMS, 2019-2025
39 companies · $3,164 in 2025
The $3,164 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $357 · 2021: $571 · 2022: $930 · 2023: $1,109 · 2024: $1,293 · 2025: $3,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,823 · Consulting Fee: $1,580 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.31 |
| Consulting Fee | $1,580.00 |
| Education | $162.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,804.75 | 2019-2025 | Erleada, Akeega, Carvykti |
| Ferring Pharmaceuticals INC. | $1,743.82 | 2019-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $585.11 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $479.93 | 2021-2025 | Botox, Lupron Depot |
| Pfizer INC. | $450.21 | 2019-2025 | |
| Astellas Pharma US INC | $439.30 | 2019-2025 | Xtandi, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $353.22 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $347.15 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $315.23 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $202.74 | 2022-2024 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $167.34 | 2019-2025 | Lynparza, Imfinzi |
| Amgen INC. | $134.82 | 2019-2020 | |
| Coloplast Corp | $118.53 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $111.01 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| C. R. Bard, INC. & Subsidiaries | $91.89 | 2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.